At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Apr 27, 2026 at 07:30 ET
CorMedix announced positive Phase III topline results from the ReSPECT trial, showing that rezafungin met the primary endpoint of non-inferiority vs. standard antimicrobial regimen in fungal-free survival at Day 90 for patients undergoing allogeneic HSCT. The drug demonstrated a favorable safety profile, particularly in reduced toxicity-related discontinuations and drug-drug interactions, supporting a potential sNDA submission in 2H26 for expanded prophylactic use.
- ReSPECT Phase III trial met primary FDA/EMA endpoint: non-inferiority in fungal-free survival at Day 90 (60.7% for rezafungin vs. 59.0% for standard regimen).
- Rezafungin showed favorable secondary outcomes in safety, including lower rates of treatment discontinuation due to adverse events and fewer drug-drug interactions.
- sNDA submission to FDA expected in 2H26, following a pre-NDA meeting.
- Rezafungin is already approved for candidemia and invasive candidiasis; this data supports expansion into prophylaxis, a potential $2B+ US market.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access